IMPORTANCE African Americans and individuals of African ancestry have a higher risk of stroke compared with non-Hispanic white individuals. Identifying the source of this disparity could provide an opportunity for clinical stroke risk stratification and more targeted therapy. Whether sickle cell trait (SCT) is an indicator of increased risk of ischemic stroke among African Americans is still unclear.
S troke is the fifth leading cause of death in the United States and a major cause of morbidity and loss of economic productivity. 1 The prevalence of stroke is higher among African American individuals compared with nonHispanic white individuals (4.5% vs 2.5%). 2 In this regard, the incidence of stroke has been steadily decreasing among nonHispanic white individuals but not among African American individuals, who also tend to experience stroke at a younger age. 1, 3 For instance, the overall age-adjusted incidence rate ratio for stroke between African American and non-Hispanic white individuals is 1.51, whereas it is 4.05 at ages 45 to 54 years but 0.86 at 85 years or older. 3 A possible genetic contribution has been hypothesized as a reason for this observed disparity because traditional risk factors were only able to explain half of the observed disparity. 4 One common potential genetic risk factor, and the focus of this article, is the sickle hemoglobin (β-globin) mutation. The sickle cell mutation is an A/T point mutation that results in the substitution of valine for glutamic acid at the sixth position of the β-globin chain. 5 The homozygous form (sickle cell anemia or HbSS), which is seen in 1 in 312 African Americans, has been associated with a wide array of complications, 6 including stroke. 7 The heterozygous state, sickle cell trait (SCT) or HbAS, which is prevalent in approximately 8% of African Americans, 8, 9 has been associated with an increased incidence and prevalence of venous thromboembolism 10 and pulmonary embolism, 11, 12 with a population attributable risk of 6% to 9% for venous thromboembolism. 10 Hypercoagulability attributable to SCT is a proposed mechanism for this association because those with SCT have higher circulating levels of D-dimer, thrombin-antithrombin complex, prothrombin fragment 1.2, and C-reactive protein compared with those without SCT. 13, 14 In addition, SCT has been associated with blood hyperviscosity, 15 tendency for polymerization of hemoglobin, 16, 17 adherence of red blood cells to the endothelial surface, 18 and increased levels of adhesion molecules. 19 In general, these pathobiological processes increase the predisposition to microvascular occlusion and ischemic stroke, but whether there is an association between SCT and incidence of stroke in African Americans has been the subject of much debate. 20, 21 Several case reports [22] [23] [24] [25] [26] have suggested an association with ischemic stroke, with a previous prospective, populationbased study 27 reporting an association between SCT and incident stroke in African Americans. The aim of our study was to provide more definitive data on the association between SCT and incident ischemic stroke in African Americans.
Methods
We conducted a meta-analysis of 4 prospective studies that were established to determine the risk factors for cardiovascular disease among diverse race/ethnicity groups in the United States. 
Genetic Assessment of SCT
Sickle cell trait was defined based on the presence of the minor allele of the rs334 single-nucleotide polymorphism encoding the HBB (OMIM 141900) p.Glu7Val mutation. The REGARDS sample was directly genotyped using a real-time polymerase chain reaction assay (TaqMan; Thermo Fisher Scientific), 27,33 whereas the JHS, MESA, and WHI were assessed using a combination of whole-exome sequencing and imputation. 34 Further details of the genotyping procedures, including imputation and quality control methods, have been published and are summarized in the eMethods in the Supplement.
9,33
Identification of Incident Ischemic Stroke
The studies followed up participants annually or semiannually to identify occurrence of cardiovascular events, including stroke. Stroke events were obtained from hospitalizations or self-report and were then adjudicated by a panel of neurologists using a combination of clinical and radiologic information. Incident ischemic stroke was defined as the first adjudicated ischemic stroke event that occurred after participants completed their study enrollment and baseline examination. The World Health Organization's definition of stroke 35 was used but without strict adherence to the duration of symptoms when clinical and radiologic evidence of a stroke was present. Additional details on case definition are provided in the eMethods in the Supplement. Individuals who self-reported a history of stroke at the baseline examination were excluded from this analysis. We also censored those with incident hemorrhagic stroke (subarachnoid and intracerebral hemorrhages).
Statistical Analysis
Participants missing relevant covariate or genotype data were excluded before data analysis except when the specific covariate was missing for all individuals in the entire cohort. In addition, individuals who were genotyped or imputed to be homozygous for rs334 or determined to have compound heterozygosity, such as HbSC, were excluded from further analysis (n = 5; 3 from the JHS and 2 from the WHI). Data on the prevalence of SCT as well as baseline demographic, risk factor, and follow-up data were tabulated as proportions or means with SDs as appropriate. The crude incidence rate of ischemic stroke in each study cohort was estimated per 1000 personyears and then meta-analyzed using inverse variance weighting a priori assuming a random-effects model because of the small number of cohorts (n = 4) and inherent heterogeneity among the study cohorts. We used Cox proportional hazards regression analysis to determine the hazard ratio (HR) for ischemic stroke among individuals with SCT compared with those without SCT, adjusting for relevant covariates. Three levels of covariate adjustment were performed. In model 1, we adjusted for age, sex, and region of residence (in REGARDS only). In model 2, in addition to the covariates in model 1, we adjusted for the components of the Framingham stroke risk score, systolic blood pressure, diabetes mellitus, cigarette smoking (current vs noncurrent except in the WHI, in which it was ever-vs neversmokers), history of cardiovascular disease, hypertension status (defined as diagnosed hypertension or current use of antihypertensive medication), history of atrial fibrillation, and history of left ventricular hypertrophy. 36, 37 In model 3, in addition to the covariates in model 2, we adjusted for principal components of global ancestry derived from the genomewide array genotyping data. The results from the Cox proportional hazards regression model and from models 1, 2, and 3 were then combined using inverse variance-weighted metaanalysis, assuming a random-effects model. We also presented the result of the meta-analysis of the fully adjusted model in a forest plot. P < .05 was considered statistically significant based on an inverse variance-weighted approach assuming a random-effects model.
Results

Baseline Characteristics
The 
Association of SCT With Incident Stroke
The analysis within each cohort and the subsequent metaanalysis ( Table 3 , the adjusted HR for ischemic stroke was not significantly different between participants with SCT and those without SCT (meta-analysis HR, 0.80; 95% CI, 0.47-1.35; P = .82) (Figure) . No associations were observed in the cohortspecific analyses or in the meta-analysis for any of the sequentially adjusted models.
Discussion
In this meta-analysis of 4 large, population-based studies, there was no evidence of a statistically significant association between SCT and risk of incident ischemic stroke in African Americans. Neither the crude incidence rate nor the Cox proportional hazards regression models indicated that SCT is a risk factor for ischemic stroke. The absence of an association between SCT and risk of ischemic stroke was consistent among the cohorts and suggests that SCT is not an independent genetic risk factor for ischemic stroke among African Americans.
Although sickle cell anemia is associated with stroke risk, previous evidence of an association between SCT and stroke was limited to case reports 22-24,26,39-41 and a single-cohort longitudinal study. 27 The latter study found a 1.4-fold (95% CI, 1.0-2.0) increased risk of ischemic stroke in SCT carriers compared with noncarriers in a population-based cohort of 3497 African Americans. A first possible reason for the inconsistency of results among studies could be because of differences in methods, such as in case ascertainment and defini- tion. However, this reason is unlikely because all the studies used similar surveillance and clinical and radiologic criteria for case identification and definition. A second possible reason is that in our study, the sample of participants with SCT who were in the age groups at greater risk of stroke (in each cohort) was relatively small; thus, differences among studies were likely caused by chance. A third possible reason relates to differences in the covariates considered. For instance, in our study, we adjusted for left ventricular hypertrophy, a component of the Framingham stroke risk score, which was not done in the prior published study. 27 However, in our analysis, adjusting for left ventricular hypertrophy did not change the direction of estimate effects.
Limitations
A limitation of our study is that approximately 48% of our sample was not directly genotyped; thus, there is a risk of misclassification of SCT status. We do not believe that misclassification accounts for our lack of association because the κ statistic for imputed vs sequenced genotypes was 0.91 (95% CI, 0.87-0.95), which is considered to indicate high-quality imputation. 34 Furthermore, the effect estimates and lack of association that we observed were similar for REGARDS and the JHS, in which all participants were directly genotyped. Finally, we were unable to test the association of SCT with ischemic stroke subtypes. Thus, it remains possible that SCT is associated with 1 or more ischemic stroke subtypes.
Conclusions
In this meta-analysis, we did not observe an association between SCT and an increased risk of stroke in African Americans. Future studies with large numbers of African Americans, longer follow-up, and carefully subtyped ischemic stroke events are needed to further elucidate the possible association of SCT with incident ischemic stroke overall and by specific ischemic stroke subtypes. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication. 
MESA
In addition to the standard MESA examinations, participants or next of kin were contacted by telephone every 9-12 months for information on interim changes in medical status. Copies of death certificates, and medical records of hospitalizations and outpatient cardiovascular diagnoses were obtained. Incident strokes were determined via adjudication by an expert panel of trained stroke neurologists (vascular neurologists). Stroke was defined as "a rapid onset of
